Comment on “Commercial landscape of noninvasive prenatal testing in the United States”

Authors


Correspondence to: Matthew Rabinowitz. E-mail: mrabinowitz@natera.com

We read with interest the recent review in Prenatal Diagnosis entitled “Commercial landscape of noninvasive prenatal testing in the United States” by Ashwin Agarwal et al.[1] We appreciate the attention afforded to the business and intellectual property landscape given by noninvasive prenatal testing's rapid evolution. However, Agarwal et al. misrepresented the current commercial turnaround time for Natera's single nucleotide polymorphism based PanoramaTM test. This is an important parameter that affects clinical implementation, and as such, we feel it is important to report the most up-to-date information. We thus wish to communicate the preliminary results of analysis of the most recent 10000 commercially-processed samples.

Specifically, Panorama now reports a turnaround time of 5 to 10 business days; >95% of the aforementioned commercial samples were processed in under 10 business days.

Ancillary